ResMed has completed the acquisition of Texas-based medical device firm Inova Labs, which is involved in developing oxygen therapy products.
Terms of the deal, which was announced first in January, have not been disclosed.
The deal allows ResMed to expand its care offerings and solutions to treat people with chronic obstructive pulmonary disease (COPD).
ResMed CEO Mick Farrell said: "We are excited to complete this acquisition, which expands our offerings and solutions to address a global COPD epidemic impacting tens of millions of people.
"This acquisition is an important step to reach our goal of improving 20 million lives by 2020."
The acquisition adds ResMed with both innovative portable oxygen concentrators and necessary stationary options for the home.
Inova Labs produces LifeChoice Activox, which is a lightweight and portable oxygen concentrator that provides enhanced battery life for freedom and mobility.
The firm also produces Activox DUO2, which is claimed to be the industry’s first fully integrated stationary and portable oxygen concentrator system.
Last October, ResMed acquired non-invasive ventilation and sleep-disordered breathing medical devices and accessories provider, Curative Medical.
Established in 2008, Curative designs and produces medical devices for sleep-disordered breathing and COPD.
With operations in around 100 countries, ResMed is involved in developing devices for the diagnosis, treatment and management of sleep-disordered breathing, COPD and other chronic conditions.
The firm currently produces respiratory care products, including AirCurve 10 series of cloud-connected non-invasive ventilators, Stellar series of non-invasive ventilators and Astral series.
Image: ResMed has acquired Texas-based medical device firm Inova Labs. Photo: courtesy of adamr / FreeDigitalPhotos.net.